KR100504292B1 - 테트라졸 유도체 - Google Patents

테트라졸 유도체 Download PDF

Info

Publication number
KR100504292B1
KR100504292B1 KR10-2003-7000350A KR20037000350A KR100504292B1 KR 100504292 B1 KR100504292 B1 KR 100504292B1 KR 20037000350 A KR20037000350 A KR 20037000350A KR 100504292 B1 KR100504292 B1 KR 100504292B1
Authority
KR
South Korea
Prior art keywords
formula
tetrazol
carboxylic acid
xanthene
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2003-7000350A
Other languages
English (en)
Korean (ko)
Other versions
KR20030016390A (ko
Inventor
졸리돈시네세
뮈텔벵상
비에이라에릭
비크만주어겐
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20030016390A publication Critical patent/KR20030016390A/ko
Application granted granted Critical
Publication of KR100504292B1 publication Critical patent/KR100504292B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2003-7000350A 2000-07-13 2001-07-05 테트라졸 유도체 Expired - Fee Related KR100504292B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00115170 2000-07-13
EP00115170.3 2000-07-13
PCT/EP2001/007692 WO2002006254A1 (en) 2000-07-13 2001-07-05 Tetrazole derivatives

Publications (2)

Publication Number Publication Date
KR20030016390A KR20030016390A (ko) 2003-02-26
KR100504292B1 true KR100504292B1 (ko) 2005-07-28

Family

ID=8169240

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7000350A Expired - Fee Related KR100504292B1 (ko) 2000-07-13 2001-07-05 테트라졸 유도체

Country Status (19)

Country Link
US (1) US6399641B1 (https=)
EP (1) EP1303499B1 (https=)
JP (1) JP3971298B2 (https=)
KR (1) KR100504292B1 (https=)
CN (1) CN1214017C (https=)
AR (1) AR029706A1 (https=)
AT (1) ATE332895T1 (https=)
AU (2) AU2001278472B2 (https=)
BR (1) BR0112465A (https=)
CA (1) CA2415673A1 (https=)
DE (1) DE60121447T2 (https=)
DK (1) DK1303499T3 (https=)
ES (1) ES2267797T3 (https=)
MX (1) MXPA03000221A (https=)
PA (1) PA8521901A1 (https=)
PE (1) PE20020409A1 (https=)
PT (1) PT1303499E (https=)
WO (1) WO2002006254A1 (https=)
ZA (1) ZA200210157B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413347A (pt) 2003-08-06 2006-10-10 Senomyx Inc novos sabores, modificadores de sabor, agentes de sabor, realçadores de sabor, agentes de sabor e/ou realçadores umami ou doces, e utilização correspondente
WO2005085214A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR101387563B1 (ko) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1343827A (en) * 1971-06-15 1974-01-16 Science Union & Cie Acylaminotetrazoles and process for preparing them
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
GB9626151D0 (en) * 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds
JP2001525390A (ja) * 1997-12-10 2001-12-11 エヌピーエス ファーマシューティカルズ インコーポレーテッド 抗痙攣薬および中枢神経系活性ビス（フルオロフェニル）アルキルアミド類
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives

Also Published As

Publication number Publication date
ES2267797T3 (es) 2007-03-16
PE20020409A1 (es) 2002-05-21
PA8521901A1 (es) 2002-04-25
CN1441791A (zh) 2003-09-10
CA2415673A1 (en) 2002-01-24
WO2002006254A1 (en) 2002-01-24
JP3971298B2 (ja) 2007-09-05
ATE332895T1 (de) 2006-08-15
AU7847201A (en) 2002-01-30
EP1303499B1 (en) 2006-07-12
EP1303499A1 (en) 2003-04-23
AR029706A1 (es) 2003-07-10
DE60121447D1 (de) 2006-08-24
AU2001278472B2 (en) 2006-08-03
JP2004504308A (ja) 2004-02-12
MXPA03000221A (es) 2003-06-06
CN1214017C (zh) 2005-08-10
DK1303499T3 (da) 2006-10-30
BR0112465A (pt) 2003-07-22
US20020022648A1 (en) 2002-02-21
ZA200210157B (en) 2004-03-15
KR20030016390A (ko) 2003-02-26
DE60121447T2 (de) 2007-02-01
PT1303499E (pt) 2006-11-30
US6399641B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
KR100504292B1 (ko) 테트라졸 유도체
EP1171423B1 (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
AU2011246072B2 (en) Tetrahydrobenzothiophene compound
JP5408434B2 (ja) アミド化合物
KR101589332B1 (ko) ２ｈ-크로멘 화합물 및 그의 유도체
US6514996B2 (en) Derivatives of benzofuran or benzodioxole
AU2001278472A1 (en) Tetrazole derivatives
BR112014010169B1 (pt) Compostos de derivado n-tienilbenzamida substituída com aminoalquil, composição contendo os ditos compostos e uso dos mesmos para prevenir ou tratar hiperfosfatemia
AU661609B2 (en) New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them
CN103772239A (zh) 新的酰胺和脒衍生物和其用途
SK285373B6 (sk) 2-(3,5-bis-Trifluórmetylfenyl)-N-metyl-N-(6-morfolin-4-yl-4-o- tolylpyridin-3-yl)izobutyramid, spôsob jeho prípravy a použitie a liečivo obsahujúce túto zlúčeninu
KR101767348B1 (ko) 대사형 글루타메이트 수용체 길항제로서의 에틴일 유도체
EP1224163B1 (en) Use of carbonylamino derivatives against cns disorders
EP0719773B1 (en) Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia
SK9312000A3 (en) N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them
CA2140953A1 (en) Polyhydronorharman synthase inhibitors
TW202411233A (zh) 用於治療trpm3介導病症之新型衍生物
JP2025517514A (ja) Ｔｒｐｍ３媒介性障害を治療するための新たな誘導体
US4958023A (en) 2-pyridinecarbothioamides, processes for preparation thereof and pharmaceutical compositions comprising the same
US5234948A (en) Optically active alkylenedioxybenzene derivatives and their use in therapy

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20080630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090721

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090721

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000